RSS feed

Publications (original articles or review articles) published in 2021 from OUS - Department of Cancer Immunology

32 publications found

Ali M, Giannakopoulou E, Li Y, Lehander M, Virding Culleton S, Yang W, Knetter C, Odabasi MC, Bollineni RC, Yang X, Foldvari Z, Böschen ML, Taraldsrud E, Strønen E, Toebes M, Hillen A, Mazzi S, de Ru AH, Janssen GMC, Kolstad A, Tjønnfjord GE, Lie BA, Griffioen M, Lehmann S, Osnes LT et al. (2021)
T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes
Nat Biotechnol, 40 (4), 488-498
DOI 10.1038/s41587-021-01089-x, PubMed 34873326

Chellappa S, Kushekhar K, Hagness M, Horneland R, Taskén K, Aandahl EM (2021)
The Presence of Activated T Cell Subsets prior to Transplantation Is Associated with Increased Rejection Risk in Pancreas Transplant Recipients
J Immunol, 207 (10), 2501-2511
DOI 10.4049/jimmunol.2001103, PubMed 34607938

de Freitas Germano J, Sharma A, Stastna M, Huang C, Aniag M, Aceves A, Van Eyk JE, Mentzer RM, Piplani H, Andres AM, Gottlieb RA (2021)
Proteomics of Mouse Heart Ventricles Reveals Mitochondria and Metabolism as Major Targets of a Post-Infarction Short-Acting GLP1Ra-Therapy
Int J Mol Sci, 22 (16)
DOI 10.3390/ijms22168711, PubMed 34445425

Dillard P, Casey N, Pollmann S, Vernhoff P, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2021)
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
Oncoimmunology, 10 (1), 1936757
DOI 10.1080/2162402X.2021.1936757, PubMed 34235003

Isaksen KT, Mastroianni MA, Rinde M, Rusten LS, Barzenje DA, Ramslien LF, Slaaen M, Jerm MB, Smeland EB, Rostoft S, Liestøl K, Brodtkorb M, Holte H (2021)
A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL
Blood Adv, 5 (22), 4771-4782
DOI 10.1182/bloodadvances.2021004777, PubMed 34543384

Jenum S, Tonby K, Rueegg CS, Rühwald M, Kristiansen MP, Bang P, Olsen IC, Sellæg K, Røstad K, Mustafa T, Taskén K, Kvale D, Mortensen R, Dyrhol-Riise AM (2021)
A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients
Nat Commun, 12 (1), 6774
DOI 10.1038/s41467-021-27029-6, PubMed 34811370

Jiang X, Bergquist A, Löscher BS, Venkatesh G, Mold JE, Holm K, Laerdahl JK, Skånland SS, Maleki KT, Cornillet M, Taskén K, Franke A, Karlsen TH, Björkström NK, Melum E (2021)
A heterozygous germline CD100 mutation in a family with primary sclerosing cholangitis
Sci Transl Med, 13 (582)
DOI 10.1126/scitranslmed.abb0036, PubMed 33627483

Jøntvedt Jørgensen M, Nore KG, Aass HCD, Layre E, Nigou J, Mortensen R, Tasken K, Kvale D, Jenum S, Tonby K, Dyrhol-Riise AM (2021)
Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients
Front Cell Infect Microbiol, 11, 669623
DOI 10.3389/fcimb.2021.669623, PubMed 34307194

Klopotowska M, Bajor M, Graczyk-Jarzynka A, Kraft A, Pilch Z, Zhylko A, Firczuk M, Baranowska I, Lazniewski M, Plewczynski D, Goral A, Soroczynska K, Domagala J, Marhelava K, Slusarczyk A, Retecki K, Ramji K, Krawczyk M, Temples MN, Sharma B, Lachota M, Netskar H, Malmberg KJ, Zagozdzon R, Winiarska M (2021)
PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress
Cancer Immunol Res, 10 (2), 228-244
DOI 10.1158/2326-6066.CIR-20-1023, PubMed 34853030

Lachota M, Lennikov A, Malmberg KJ, Zagozdzon R (2021)
Bioinformatic Analysis Reveals Central Role for Tumor-Infiltrating Immune Cells in Uveal Melanoma Progression
J Immunol Res, 2021, 9920234
DOI 10.1155/2021/9920234, PubMed 34195299

Langenbucher A, Bowen D, Sakhtemani R, Bournique E, Wise JF, Zou L, Bhagwat AS, Buisson R, Lawrence MS (2021)
An extended APOBEC3A mutation signature in cancer
Nat Commun, 12 (1), 1602
DOI 10.1038/s41467-021-21891-0, PubMed 33707442

Lone AM, Giansanti P, Jørgensen MJ, Gjerga E, Dugourd A, Scholten A, Saez-Rodriguez J, Heck AJR, Taskén K (2021)
Systems approach reveals distinct and shared signaling networks of the four PGE₂ receptors in T cells
Sci Signal, 14 (703), eabc8579
DOI 10.1126/scisignal.abc8579, PubMed 34609894

Lone AM, Taskén K (2021)
Phosphoproteomics-Based Characterization of Prostaglandin E₂ Signaling in T Cells
Mol Pharmacol, 99 (5), 370-382
DOI 10.1124/molpharm.120.000170, PubMed 33674363

Lorvik KB, Meyer-Myklestad MH, Kushekar K, Handeland C, Medhus AW, Lund-Iversen M, Stiksrud B, Kvale D, Dyrhol-Riise AM, Taskén K, Reikvam DH (2021)
Enhanced Gut-Homing Dynamics and Pronounced Exhaustion of Mucosal and Blood CD4⁺ T Cells in HIV-Infected Immunological Non-Responders
Front Immunol, 12, 744155
DOI 10.3389/fimmu.2021.744155, PubMed 34691047

Maclachlan KH, Rustad EH, Derkach A, Zheng-Lin B, Yellapantula V, Diamond B, Hultcrantz M, Ziccheddu B, Boyle EM, Blaney P, Bolli N, Zhang Y, Dogan A, Lesokhin AM, Morgan GJ, Landgren O, Maura F (2021)
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
Nat Commun, 12 (1), 5172
DOI 10.1038/s41467-021-25469-8, PubMed 34453055

Maura F, Boyle EM, Rustad EH, Ashby C, Kaminetzky D, Bruno B, Braunstein M, Bauer M, Blaney P, Wang Y, Ghamlouch H, Williams L, Stoeckle J, Davies FE, Walker BA, Maclachlan K, Diamond B, Landgren O, Morgan GJ (2021)
Chromothripsis as a pathogenic driver of multiple myeloma
Semin Cell Dev Biol, 123, 115-123
DOI 10.1016/j.semcdb.2021.04.014, PubMed 33958284

Mazzarella L, Enblad G, Olweus J, Malmberg KJ, Jerkeman M (2021)
Advances in immune therapies in hematological malignancies
J Intern Med, 292 (2), 205-220
DOI 10.1111/joim.13395, PubMed 34624160

Melvold K, Giliberto M, Karlsen L, Ayuda-Durán P, Hanes R, Holien T, Enserink J, Brown JR, Tjønnfjord GE, Taskén K, Skånland SS (2021)
Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies
Mol Oncol, 16 (5), 1153-1170
DOI 10.1002/1878-0261.13153, PubMed 34861096

Mensali N, Dillard P, Fayzullin A, Köksal H, Gaudernack G, Kvalheim G, Inderberg EM, Wälchli S (2021)
"Built-in" PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms
FASEB J, 35 (9), e21750
DOI 10.1096/fj.202100025R, PubMed 34424568

Mester S, Evers M, Meyer S, Nilsen J, Greiff V, Sandlie I, Leusen J, Andersen JT (2021)
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
MAbs, 13 (1), 1893888
DOI 10.1080/19420862.2021.1893888, PubMed 33691596

Oksvold MP, Berglund UW, Gad H, Bai B, Stokke T, Rein ID, Pham T, Sanjiv K, Øy GF, Norum JH, Smeland EB, Myklebust JH, Helleday T, Våtsveen TK (2021)
Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
Sci Rep, 11 (1), 6317
DOI 10.1038/s41598-021-85613-8, PubMed 33737576

Reint G, Li Z, Labun K, Keskitalo S, Soppa I, Mamia K, Tolo E, Szymanska M, Meza-Zepeda LA, Lorenz S, Cieslar-Pobuda A, Hu X, Bordin DL, Staerk J, Valen E, Schmierer B, Varjosalo M, Taipale J, Haapaniemi E (2021)
Rapid genome editing by CRISPR-Cas9-POLD3 fusion
Elife, 10
DOI 10.7554/eLife.75415, PubMed 34898428

Rustad EH, Nadeu F, Angelopoulos N, Ziccheddu B, Bolli N, Puente XS, Campo E, Landgren O, Maura F (2021)
mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies
Commun Biol, 4 (1), 424
DOI 10.1038/s42003-021-01938-0, PubMed 33782531

Rye IH, Huse K, Josefsson SE, Kildal W, Danielsen HE, Schlichting E, Garred Ø, Riis ML, Osbreac, Lingjaerde OC, Myklebust JH, Russnes HG (2021)
Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppression
Mol Oncol, 16 (1), 88-103
DOI 10.1002/1878-0261.13047, PubMed 34165864

Sanjiv K, Calderón-Montaño JM, Pham TM, Erkers T, Tsuber V, Almlöf I, Höglund A, Heshmati Y, Seashore-Ludlow B, Nagesh Danda A, Gad H, Wiita E, Göktürk C, Rasti A, Friedrich S, Centio A, Estruch M, Våtsveen TK, Struyf N, Visnes T, Scobie M, Koolmeister T, Henriksson M, Wallner O, Sandvall T et al. (2021)
MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia
Cancer Res, 81 (22), 5733-5744
DOI 10.1158/0008-5472.CAN-21-0061, PubMed 34593524

Sioud M (2021)
RNA Interference: Story and Mechanisms
Methods Mol Biol, 2282, 1-15
DOI 10.1007/978-1-0716-1298-9_1, PubMed 33928566

Sioud M, Juzenas P, Zhang Q, Kleinauskas A, Peng Q (2021)
Evaluation of In Vitro Phototoxicity of a Minibody-IR700 Conjugate Using Cell Monolayer and Multicellular Tumor Spheroid Models
Cancers (Basel), 13 (13)
DOI 10.3390/cancers13133356, PubMed 34283089

Skånland SS, Mato AR (2021)
Overcoming resistance to targeted therapies in chronic lymphocytic leukemia
Blood Adv, 5 (1), 334-343
DOI 10.1182/bloodadvances.2020003423, PubMed 33570649

Spasevska I, Myklebust JH (2021)
What It Takes to Transform a T Cell
Cancer Res, 81 (12), 3160-3161
DOI 10.1158/0008-5472.CAN-21-0784, PubMed 34224376

Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, Kurtz DM, Liu CL, Khameneh F, Advani RH, Natkunam Y, Myklebust JH, Diehn M, Gentles AJ, Newman AM, Alizadeh AA (2021)
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma
Cancer Cell, 39 (10), 1422-1437.e10
DOI 10.1016/j.ccell.2021.08.011, PubMed 34597589

Sullivan LC, Nguyen THO, Harpur CM, Stankovic S, Kanagarajah AR, Koutsakos M, Saunders PM, Cai Z, Gray JA, Widjaja JML, Lin J, Pietra G, Mingari MC, Moretta L, Samir J, Luciani F, Westall GP, Malmberg KJ, Kedzierska K, Brooks AG (2021)
Natural killer cell receptors regulate responses of HLA-E-restricted T cells
Sci Immunol, 6 (58)
DOI 10.1126/sciimmunol.abe9057, PubMed 33893172

Woan KV, Kim H, Bjordahl R, Davis ZB, Gaidarova S, Goulding J, Hancock B, Mahmood S, Abujarour R, Wang H, Tuininga K, Zhang B, Wu CY, Kodal B, Khaw M, Bendzick L, Rogers P, Ge MQ, Bonello G, Meza M, Felices M, Huffman J, Dailey T, Lee TT, Walcheck B et al. (2021)
Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy
Cell Stem Cell, 28 (12), 2062-2075.e5
DOI 10.1016/j.stem.2021.08.013, PubMed 34525347